No Data
Henlius Doses First Patient in Phase 3 Study of Combo Treatment for Gastric Cancer
Shanghai Henlius Advances Privatization Plans With Fosun
Shanghai Henlius Biotech Begins Phase 3 Trial for Cancer Therapy
Henlius (02696.HK): The international multicenter Phase 3 clinical study in mainland China comparing HLX22 combined with trastuzumab and XELOX chemotherapy to trastuzumab and XELOX with or without ramucirumab as first-line treatment for locally advanced o
Gelonghui November 22nd | Henlius (02696.HK) announced that recently, a Phase III international multicenter clinical trial of HLX22 (recombinant humanized anti-HER2 monoclonal antibody injection) compared HLX22 in combination with trastuzumab and XELOX chemotherapy to trastuzumab and XELOX chemotherapy alone or in combination with pembrolizumab for first-line treatment of locally advanced or metastatic gastroesophageal junction and gastric cancer has completed the first patient dosing in mainland china. This study is a double-blind, international multicenter, randomized controlled Phase III study designed to compare HLX22 in combination with trastuzumab.
Express News | Henlius: On Morning of Nov 7, Entered Into a Strategic Collaboration With Al-Tiryaq Al-Khalawi Medical Company
Henlius and SVAX Forge Strategic Partnership in the MENAT Market
No Data
No Data
